Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Neurology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters

Alzheimer's Disease Clinical Trials

A listing of Alzheimer's Disease medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (39) clinical trials

Patient Inclusion Criteria: Ages: over 55-90 Male/Female 12 Month Long Clinical Trial MMSE score 24-30/20-26 Subjects must meet criteria for Prodromal AD or Mild AD: Mini Mental State Examination (MMSE) score between 20-30 Clinical Dementia Rating Scale (CDR) score of 0.5 or 1 a free recall score of lesser or ...


If you qualify, the study may involve 4 in-clinic stays,2 outpatient visits, and 1 telephone follow up. The in-clinic stays will consist of 3 days and 2 nights. You do not need medical insurance to participate in this research study.


If you qualify, the study may involve 3 screening visits, 1 separate in-clinic stay of 5 days/4 nights and 10 outpatient visits. All study exams and procedures are provided at no cost to you. You do not need medical insurance to participate.


This study will evaluate the safety and efficacy of NPT088 or Placebo in participants with probable Alzheimer's Disease


Allogeneic Human Mesenchymal Stem Cell Infusion Versus Placebo in Patients With Alzheimer's Disease

This is a randomized, placebo-controlled clinical trial designed to evaluate the safety and efficacy of LMSCs (Longeveron Mesenchymal Stem Cells) or placebo in subjects with Alzheimer's Disease. Following a successful Safety Run-In Phase, a total of twenty-five (25) subjects will be randomized to (2:2:1) to receive low-dose LMSCs, high-dose LMSCs ...


[11C]MK-6884 Positron Emission Tomography (PET) Tracer Validation Trial (MK-6884-001)

The purpose of this open-label, 3-part study is to investigate the safety and efficacy of [11C]MK-6884 as a Positron Emission Tomography (PET) imaging agent for quantifying muscarinic 4 (M4) positive allosteric modulator (PAM) receptor density in brain regions of interest. The study will enroll healthy participants (Parts I and II) ...


A Study of LY3002813 in Participants With Memory Damage Due to Alzheimer's Disease (AD) or AD

The study will evaluate the effect of LY3002813 on brain scans. The study will evaluate the safety of LY3002813 by looking at adverse events (side effects). The study will also look at the effect the body has on LY3002813. Study participants will have mild cognitive impairment (MCI) due to AD ...


Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia Alzheimer's Disease and Healthy Volunteers

Single site, parallel-group, double-blind trial of low or high dose of BI 409306 to evaluate the ocular and systemic safety and pharmacokinetics during 14 day treatment period in patients with schizophrenia, Alzheimer's disease, or age comparable healthy volunteers.


Study of Nasal Insulin to Fight Forgetfulness - Short-Acting Insulin Aspart

A growing body of evidence suggests that insulin plays a role in normal memory processes and that insulin abnormalities may contribute to cognitive and brain changes associated with Alzheimer's disease (AD). Interestingly, insulin administered to the nasal cavity is transported within a few minutes into the brain, but does not ...